Inactive Instrument

AltheaDx Inc Stock

US0214771042

Healthcare Facilities & Services

End-of-day quote Nasdaq
-	-

Managers and Directors: AltheaDx Inc

Manager	Title	Age	Since
David Nikodem CEO	Chief Executive Officer	56	2018-11-30
Feng Cao COO	Chief Operating Officer	-	2015-01-31
Dan Mercola PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
François Ferré CHM	Chairman	68	-
David Nikodem BRD	Director/Board Member	56	2015-11-30
Derek Maetzold BRD	Director/Board Member	64	2021-05-25

More insiders

Medical & Diagnostic Laboratories

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NATERA, INC.	+0.92%	+11.69%	+153.15%	+817.41%	59.47B
LABCORP HOLDINGS INC.	+0.22%	-3.45%	+10.35%	+50.78%	25.11B
SONIC HEALTHCARE LIMITED	-0.63%	-2.34%	-11.16%	-38.35%	6.52B
RADNET, INC.	-0.73%	-6.86%	-6.74%	+154.37%	5.57B
DR. LAL PATHLABS LIMITED	-0.46%	+2.92%	+22.23%	+61.31%	3.4B
GENEDX HOLDINGS CORP.	-0.09%	-12.56%	-24.58%	+2,376.19%	2.64B
NEOGENOMICS, INC.	-1.18%	-2.91%	+143.76%	+57.03%	2.48B
FLEURY S.A.	+16.38%	+1.68%	+35.11%	+45.42%	2.27B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	+1.10%	+4.93%	+0.79%	-53.43%	2B
Average	+1.73%	-0.64%	+35.88%	+385.64%	12.16B
Weighted average by Cap.	+0.79%	+4.90%	+88.67%	+521.68%

See all sector performances

AltheaDx, Inc. is a United States-based molecular diagnostics company. The Company is specialized in the field of pharmacogenetics. The Company focuses on enabling physicians, managed care organizations, pharmaceutical companies and other healthcare entities to make personalized therapeutic decisions for patients. The Company's IDgenetix pharmacogenetic testing portfolio addresses various clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain. The IDgenetix testing process consists of three steps: drug metabolism genotyping, drug response genotyping and algorithm screening. Its algorithm-based bioinformatic platform and pharmacogenetics product testing portfolio are intended to serve as a tool to assist healthcare providers in identifying optimal drugs for their patients, as well as dosing guidelines based on a patient's genetic make-up, prescription regimen and other factors.

Employees

Sector

Healthcare Facilities & Services

More about the company